A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MITAPIVAT IN PATIENTS WITH SICKLE CELL DISEASE
a Division of Hematology, University of Toronto, Toronto, Canada
b Agios Pharmaceuticals, Inc., Cambridge, United States
c Van Creveldkliniek, Department of Internal Medicine, University Medical Center Utrecht, Utrecht, Netherlands
d Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, United States
Read
1558
Timeswas read the article
659
Total PDF
899
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 7 | 18 | 3 | 21 |
| 2025 6 | 46 | 22 | 68 |
| 2025 5 | 47 | 14 | 61 |
| 2025 4 | 38 | 27 | 65 |
| 2025 3 | 69 | 14 | 83 |
| 2025 2 | 39 | 15 | 54 |
| 2025 1 | 27 | 23 | 50 |
| 2024 12 | 29 | 9 | 38 |
| 2024 11 | 37 | 23 | 60 |
| 2024 10 | 32 | 25 | 57 |
| 2024 9 | 45 | 20 | 65 |
| 2024 8 | 46 | 24 | 70 |
| 2024 7 | 39 | 27 | 66 |
| 2024 6 | 42 | 27 | 69 |
| 2024 5 | 45 | 32 | 77 |
| 2024 4 | 31 | 14 | 45 |
| 2024 3 | 18 | 22 | 40 |
| 2024 2 | 17 | 27 | 44 |
| 2024 1 | 15 | 15 | 30 |
| 2023 12 | 18 | 18 | 36 |
| 2023 11 | 23 | 27 | 50 |
| 2023 10 | 18 | 29 | 47 |
| 2023 9 | 19 | 31 | 50 |
| 2023 8 | 9 | 15 | 24 |
| 2023 7 | 16 | 9 | 25 |
| 2023 6 | 20 | 22 | 42 |
| 2023 5 | 19 | 17 | 36 |
| 2023 4 | 11 | 13 | 24 |
| 2023 3 | 12 | 15 | 27 |
| 2023 2 | 14 | 14 | 28 |
| 2023 1 | 7 | 10 | 17 |
| 2022 12 | 17 | 27 | 44 |
| 2022 11 | 12 | 19 | 31 |
| 2022 10 | 4 | 10 | 14 |
Show all
